Marker | Specimen | Use |
---|---|---|
MSI | Tumor | Determine eligibility for anti-PD1 treatment |
Quant HCV | Serum | Response to anti-CTLA-4 treatment in patients with HCV infection |
Pathology | Liver biopsy | Rule out drug induced hepatitis |
ALT/AST | Serum | Liver toxicity |
Gut microbiome | Stool | Response to treatment with immune checkpoint inhibitors |